Clinical Trials Sponsored by Sirtex Medical

Total 55674 results

Sirtex Medical

Completed

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)

Intrahepatic Cholangiocarcinoma

France, United Kingdom, Belgium, Australia, Spain, United States, Italy, Netherlands
Sirtex Medical

Completed

SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma (SIRTACE)

Hepatocellular Carcinoma

Germany, Spain
Sirtex Medical

Withdrawn

FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma (FAST)

Liver Metastases | Colorectal Carcinoma

United States
Sirtex Medical

Recruiting

Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry) (SIRtain)

Unresectable Hepatocellular Carcinoma (HCC) | Liver Metastases From Colorectal Cancer (mCRC)

Spain, United Kingdom, France
Sirtex Medical

Terminated

SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular | Hepatoma

United States
Sirtex Medical

Completed

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer (FOXFIREGlobal)

Colorectal Cancer Metastatic

United States, France, Korea, Republic of, Australia, Israel, Singapore, Belgium, Taiwan, Spain, New Zealand, Portugal, Germany, Italy
Sirtex Medical

Completed

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (SIRFLOX)

Colorectal Cancer | Liver Metastases | Colorectal Carcinoma

United States, Israel, Australia, Belgium, New Zealand, Spain, Germany, Switzerland, Italy, France, Poland
Sirtex Medical
Bright Research Partners

Recruiting

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (DOORwaY90)

Unresectable Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Carcinoma

United States
Roger Williams Medical Center
Sirtex Medical

Completed

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases (HITM-SIR)

Liver Metastases

United States
Sirtex Medical
Bright Research Partners

Completed

SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA (MAApping)

Carcinoma | Carcinoma, Hepatocellular | Liver Neoplasm

United States
University of Magdeburg
Sirtex Medical

Completed

Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity (ELDORADO)

Colorectal Cancer | Liver Metastases | Irradiation Damage | Radiation Induced Liver Disease

Germany
University of Magdeburg
Sirtex Medical

Completed

Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy (EXPLOSIVE)

Colorectal Cancer | Liver Metastases

Germany
Andrew Kennedy
Sirtex Medical

Unknown

Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project (MORE)

Colorectal Cancer | Liver Metastases

United States
M.D. Anderson Cancer Center
Sirtex Medical

Recruiting

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Metastases

United States
SCRI Development Innovations, LLC
Sirtex Medical

Completed

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

Colorectal Neoplasms

United States
M.D. Anderson Cancer Center
Sirtex Medical

Withdrawn

Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver

Colorectal Cancer | Colon Cancer
University of Magdeburg
Bayer; Sirtex Medical

Completed

Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer (SORAMIC)

Hepatocellular Carcinoma

Germany
Fox Chase Cancer Center
Sirtex Medical

Completed

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

Metastatic Liver Cancer

United States
Memorial Sloan Kettering Cancer Center
Sirtex Medical

Completed

Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy

Rectal Cancer | Colon Cancer

United States
Emory University
National Cancer Institute (NCI); Sirtex Medical

Withdrawn

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Metastatic Carcinoma in the Liver

United States
Rutgers, The State University of New Jersey
Sirtex Medical

Completed

Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT

Liver Cancer

United States
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; AstraZeneca; Sirtex Medical

Recruiting

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Cholangiocarcinoma | Bile Duct Cancer | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma Metastatic | Metastatic Intrahepatic Cholangiocarcinoma

United States
University of California, San Francisco
Taiho Pharmaceutical Co., Ltd.; Sirtex Medical

Completed

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Rectal Cancer | Colon Cancer | Liver Metastases

United States
Tony Reid, M.D., Ph.D.
Sirtex Medical

Terminated

A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver

Liver Neoplasms | Colorectal Neoplasms

United States
Jiping Wang, MD, PhD
AstraZeneca; Sirtex Medical

Recruiting

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Hepatocellular Carcinoma | Hepatocellular Cancer | Resectable Hepatocellular Carcinoma

United States
Universitätsklinikum Köln
Sirtex Technology Pty LTD, Australia

Recruiting

European SIR-Spheres Surgical Registry (ESSURE)

Hepatectomy

Germany
Clinica Universidad de Navarra, Universidad de...
Bristol-Myers Squibb; Sirtex Medical

Completed

A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC (NASIR-HCC)

Hepatocellular Carcinoma

Spain
National Cancer Centre, Singapore
Hoffmann-La Roche; Sirtex Medical; Singapore Clinical Research Institute

Recruiting

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients (STRATUM)

Locally Advanced Hepatocellular Carcinoma

Korea, Republic of, Singapore
BioTex, Inc.

Not yet recruiting

Pivotal Voyager Ark Device Vascular Access Study (ACT II)

Vascular Access Complication | Dialysis; Complications
BioTex, Inc.

Completed

Laser Interstitial Thermal Therapy Under "Real Time" MRI Guidance for "Minimal Invasive" Treatment of Liver Metastasis

Digestive System Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms

France
BioTex, Inc.

Completed

MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors

Brain Neoplasms | Brain Cancer | Brain Tumor | Recurrent Brain Tumor

France
Medical University of South Carolina
Vertex Pharmaceuticals Incorporated

Completed

An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Not yet recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Pain
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Sickle Cell Disease
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis

United Kingdom, Canada
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

Renal Impairment

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

Diabetic Peripheral Neuropathy

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants

Pain

Australia
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Cystic Fibrosis

United States, Canada, Australia, Ireland, Germany, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Spain, Belgium, Australia, Canada, Czechia
Vertex Pharmaceuticals Incorporated

Completed

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Glomerulosclerosis, Focal Segmental

United States, France, United Kingdom, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Israel, Australia, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Subjects 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland

Clinical Trials Sponsored by Sirtex Medical

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations